Physician profile
Eric C Smith
NPI 1215485156
$4,991.99
in general payments reported to CMS, 2019-2025
29 companies · $1,950 in 2025
The $1,950 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $591 · 2022: $519 · 2023: $1,307 · 2024: $625 · 2025: $1,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,882.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,245.41 | 2021-2025 | Cabenuva, Rukobia, Apretude |
| Gilead Sciences, INC. | $847.85 | 2023-2025 | Biktarvy, Yeztugo, Descovy |
| Abbvie INC. | $363.93 | 2023-2024 | |
| Genzyme Corporation | $314.40 | 2021-2023 | |
| Theratechnologies INC. | $261.80 | 2023-2025 | Egrifta, Trogarzo |
| Lilly USA, LLC | $166.00 | 2025 | Zepbound, Mounjaro |
| Jazz Pharmaceuticals INC. | $148.64 | 2022 | |
| Esperion Therapeutics, INC. | $124.84 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $123.84 | 2022 | |
| Janssen Biotech, INC. | $121.70 | 2023 | Darzalex, Carvykti, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $121.13 | 2023 | Livtencity |
| Teva Pharmaceuticals USA, INC. | $121.12 | 2022 | |
| Napo Pharmaceuticals INC | $120.82 | 2024 | Mytesi |
| Bayer Healthcare Pharmaceuticals INC. | $108.99 | 2024 | |
| Abiomed | $102.97 | 2023 | Impella |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $100.79 | 2023 | Symtuza |
| Corcept Therapeutics | $100.00 | 2024 | Korlym |
| Incyte Corporation | $97.07 | 2021 | |
| Recordati_rare_diseases_inc. | $83.10 | 2021 | |
| Genentech USA, INC. | $79.69 | 2021 | |
| Emd Serono, INC. | $50.55 | 2025 | |
| Inspire Medical Systems, INC. | $42.27 | 2024 | Inspire |
| Antares Pharma, INC. | $37.41 | 2025 | Xyosted |
| Novo Nordisk INC | $23.19 | 2025 | Wegovy |
| Vertex Pharmaceuticals Incorporated | $21.25 | 2025 | |
| Exact Sciences Corporation | $17.50 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $16.04 | 2025 | Zoryve |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 | |
| Pfizer INC. | $14.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.